

Funding Opportunities October 2025				
Pfzer	Improving Shared Decision Making in Hemophilia: Visiting Professorship Program			10/28/2025
NIH	PAR-23-22 HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01) Standard AIDS			1/8/2026
NIH	PAR-23-073 Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01)			5/8/2026
Merkin Peripheral Neuropathy and Nerve Regeneration Center	Micro Grants	\$20,000	Rolling basis through July 1, 2026	Within 4 weeks
Office of the Vice Provost for Research	JHU Pivot Grants	\$150,000	Rolling basis	TBD
NIH	White House Initiative on Women's Health Research			11/5/2027
NIH Extramural Loan Repayment Programs (LRP) Application Cycle is NOW OPEN!	LRP website	\$100,000		11/20/2025
Funding Opportunity! Johns Hopkins and Kaiser Permanente Research Collaboration Pilot Awards	PROGRAM OVERVIEW			12/5/2025
Johns Hopkins School of Medicine	Tilghman Traveling Fellowship		1/24/1941	Rolling basis
The Ignite Fund	The Ignite Fund		Typically, \$1,000	Rolling basis

On behalf of the [Fogarty International Center](#) at the U.S. National Institutes of Health (NIH), the following funding opportunities, notices, and announcements **may be of interest to those working in the field of global health research**. Updates are typically distributed once a week.

Special Announcements

Updated implementation guidance of NIH policy on foreign subawards for active projects

As previously announced, NIH will not issue awards to domestic or foreign entities (new, renewal, or non-competing continuation) that include a subaward to a foreign entity. This Guide Notice updates the policy concerning existing projects that were active before May 1, 2025, and applications submitted on or before May 1, 2025.

- [Read full policy notice](#) (NOT-OD-25-130)

Upcoming Deadlines for Fogarty Funding Opportunities

- [International Research Scientist Development Award \(IRSDA\)](#)
Application deadline: March 9, 2026
 - [Mobile Health \(mHealth\)](#)
Application deadline: March 20, 2026
 - [Global Infectious Diseases](#)
Application deadline: August 6, 2026
-  [Upcoming deadlines for all Fogarty funding opportunities](#)

Funding opportunities on which Fogarty is a partner:

- [Dissemination and Implementation Research in Health \(R03 Clinical Trial Not Allowed\)](#) (PAR-25-233)
Application due date: Multiple dates, see announcement.
- [Dissemination and Implementation Research in Health \(R21 Clinical Trial Optional\)](#) (PAR-25-143)
Application due date: Multiple dates, see announcement.

Administrative supplements for current Fogarty grant recipients:

- [Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development \(K\) Award Recipients and Scholars](#) (NOT-OD-23-031)
Expiration date: October 1, 2025
 - [Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards](#) (NOT-OD-23-032)
Expiration date: October 1, 2025
-  [All administrative supplements](#)

Funding Opportunities

NIH funding opportunities focusing on global health and foreign collaboration:

- [Notice of Special Interest: Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program \(BRCP\) - U.S. Entity \(Admin Supp\)](#) (NOT-NS-23-092)
Application due date: September 19, 2025
 - [Pragmatic Trials across the Cancer Control Continuum \(UG3/UH3 Clinical Trial Required\)](#) (PAR-25-072)
Application due date: October 17, 2025
-  [More NIH funding opportunities focused on areas relevant to global health](#)

NIH funding opportunities for which foreign organizations and/or foreign components of U.S. organizations may apply:

- [Mucosal Immunology Studies Team \(MIST\) \(U01 Clinical Trial Not Allowed\)](#) (RFA-AI-25-018)
Application Receipt Date(s): October 21, 2025
- [Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease \(R01 Clinical Trial Not Allowed\)](#) (RFA-AI-25-022)
Application Receipt Date(s): November 7, 2025
- [Tuberculosis Research Units \(P01 Clinical Trial Optional\)](#) (RFA-AI-25-027)
Application Receipt Date(s): November 7, 2025

NIH funding opportunities for which foreign components may apply:

- [Aging Mammalian Tissues In Vitro \(R21 Clinical Trial Not Allowed\)](#) (RFA-AG-26-014)
Application Receipt Date(s): October 20, 2025
- [Native American Research Centers for Health \(NARCH\) Planning Grants \(R34 - Clinical Trial Not Allowed\)](#) (PAR-25-441)
Application Receipt Date(s): Multiple dates, see announcement.

Request for Proposals (RFP)

New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Date RFP Issued: September 3, 2025

Geographic Scope: United States and Europe are the priority regions although proposals with global reach are encouraged

Clinical Area: Genitourinary

Link to full RFP: [New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer \(mCRPC\)](#)

Application Due Date: October 14, 2025

Specific Area of Interest:

- differentiated mechanism of action (MOA) of emerging therapies including EZH2 inhibition and its possible role in prostate cancer¹
- EZH2 and other novel mechanisms of disease (MOD) and their role in prostate cancer progression²
- the investigational thesis of how concomitant EZH2 and AR inhibition may suppress prostate cancer while delaying or overcoming ARPi resistance³
- the continued unmet need for novel therapies in mCRPC
- mCRPC therapies beyond chemotherapy
- ongoing clinical trials that may be an option for patients today